ElahereTM, the first FDA-approved ADC targeting folate receptor α (FRα), demonstrates remarkable efficacy in platinum-resistant ovarian cancer but causes keratitis and other ocular toxicities in some patients. This evidence concerns the gene FOLR1 and ovarian carcinoma.